Industry71°

Isomorphic Labs 融资 50 亿美元,推进药物候选分子进入临床试验

Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials

Why we picked it

DeepMind 分拆出来的 AI 制药公司刚拿了 50 亿美元,打算把算法设计的候选药推进到临床试验。全球估计没几笔这么大的 C 轮,做药物研发或关注 AI 应用落地的朋友可以看看它是怎么用 AlphaFold 技术设计分子的。

Isomorphic Labs 完成规模达 50 亿美元的 C 轮融资。这家公司于 2021 年从 Google 旗下 DeepMind 分拆出来,主打 AI 药物发现平台,本轮资金将用于把其设计的药物候选分子推进到临床试验阶段。

Image · techcrunch
Body

公司基于 DeepMind 在蛋白质结构预测方面的研究成果(AlphaFold 相关技术)开展药物设计,通过计算方法预测分子与靶点的相互作用,从而缩短传统药物研发中筛选候选分子的周期。此次融资是该领域的标志性规模,也反映出资本对 AI 制药从实验室走向临床这一阶段的押注。

对制药和生物技术行业而言,这意味着 AI 药物发现公司开始承担更高成本的临床验证环节,其计算设计管线能否在人体试验中兑现早期结果,将成为检验这类平台商业模式的直接依据。

Original · techcrunch

Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised $5 Billion in a Series C funding round.

Industry Coordinates & Source Verification

This report is categorized under AITOP's "Industry" desk, focusing on US frontier AI labs and Silicon Valley technology leaders. Within our cross-regional analytical framework, it directly maps to AI developer toolchains, coding agents, and engineering workflows. Key entities and technical topics under continuous tracking include Isomorphic Labs, DeepMind, AI drug discovery, funding.

Source attribution: curated from techcrunch (@Ram Iyer).